Deep Dive: FDA to revoke Red No. 3 authorization
January 15th 2025, the FDA announced that they would be revoking their authorizations for Red No. 3 in food and ingested drugs. The Lycored team comments on the situation.
We’re proud to announce that Nutrition Industry Executive named us Supplier of the Month for September. In a recent interview with the magazine, CEO Rony Patishi-Chillim discussed our ongoing clinical skincare research, the inspiration behind our rebranding, our vision for the future, and our upcoming 20th anniversary (which we’ll be celebrating this October with an event in New York).
According to her, “This milestone allows us to reaffirm our commitment to our people and our partnerships, to stay true to our creative roots, and to continue improving our sustainable business foundation to better serve us now and in the future.”
January 15th 2025, the FDA announced that they would be revoking their authorizations for Red No. 3 in food and ingested drugs. The Lycored team comments on the situation.
In our latest webinar, Elizabeth Tarshish, PhD, Head of Scientific Value & Strategy at Lycored discusses Lycomato’s impact on cellular and mitochondrial health and how it promotes longevity through a...
Reflecting on my fourth year at Lycored, I'm filled with gratitude for our incredible journey together in 2024.
Interested in speaking directly with a member of our team?
Click below to get in touch.